Empirical versus Preemptive Antifungal Therapy for High‐Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial

2009386 citationsJournal Article

Authors

Catherine Cordonnier · Assistance Publique – Hôpitaux de Paris

Cécile Pautas · Assistance Publique – Hôpitaux de Paris

Sébastien Maury · Université Paris-Est Créteil

Anne Vekhoff · Assistance Publique – Hôpitaux de Paris

H. Farhat · Hôpital André Mignot

Felipe Suárez · Assistance Publique – Hôpitaux de Paris

Nathalie Dhédin

Abstract

Preemptive treatment increased the incidence of invasive fungal disease, without increasing mortality, and decreased the costs of antifungal drugs. Empirical treatment may provide better survival rates for patients receiving induction chemotherapy.

Topics & Keywords

Antifungal resistance and susceptibility Neutropenia and Cancer Infections Fungal Infections and Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

Volume 48, Issue 8, pp. 1042-1051

DOI: 10.1086/597395

Field-Weighted Citation Impact: 19.94